From Trials to Triumph—Glenmark Launches Game-Changing Immunotherapy

Image Source: ET HealthWorld

Glenmark Pharmaceuticals Ltd (NSE: GLEN.NS) has rolled out Tevimbra (tislelizumab) in India, which is a significant addition to the oncology portfolio of the company. Tevimbra is an immune checkpoint inhibitor of PD-1 that is intended to treat cancer like NSCLC and ESCC. The roll-out is in line with Glenmark's endeavor to bring innovative immuno-oncology therapies to Indian patients.

1. About Tevimbra

Tevimbra (tislelizumab) is an immune checkpoint inhibitor monoclonal antibody against the PD-1 receptor that helps the immune system to recognize and eliminate cancer cells.
It has shown promising efficacy and safety profiles in several cancer types in clinical trials.
The drug is already approved in most countries globally and now being launched in India under Glenmark's oncology business division.

2. Strategic Implications

The launch solidifies Glenmark's foothold in the immuno-oncology space, a rapidly emerging category in cancer treatment.
It is part of the company's strategic initiative to expand access to innovative treatments and address unmet medical needs in India.
Tevimbra will be competitively priced to improve affordability and accessibility to Indian patients.

3. Market Outlook

India's oncology pharma market is likely to grow at a CAGR of over 12%, driven by increasing incidence of cancer and need for improved treatments.
Glenmark's launch with Tevimbra positions it to make headway in the high-value biologics segment, especially in lung and esophageal cancers.

Sources: Glenmark Pharmaceuticals, Economic Times